Picton Mahoney Asset Management’s Apellis Pharmaceuticals APLS Stock Holding History

Picton Mahoney Asset Management’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-150,000	Closed	-$6.03M	–	1400
2026 Q1	$6.03M	Buy	+150,000	New	+$3.23M	0.04%	328
2024 Q1	–	Sell	-41,521	Closed	-$2.49M	–	389
2023 Q4	$2.49M	Sell	41,521 -27,556	-40%	-$1.4M	0.07%	187
2023 Q3	$2.63M	Buy	69,077 +26,350	+62%	+$1.16M	0.08%	184
2023 Q2	$3.89M	Sell	42,727 -6,048	-12%	-$522K	0.17%	166
2023 Q1	$3.22M	Buy	48,775 +15,249	+45%	+$880K	0.14%	187
2022 Q4	$1.73M	Buy	33,526 +2,676	+9%	+$142K	0.08%	318
2022 Q3	$2.11M	Buy	+30,850	New	+$1.83M	0.08%	281

Other funds holding APLS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Picton Mahoney Asset Management's APLS Position: Q2 2026 in Review

Picton Mahoney Asset Management sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 150,000 shares — an estimated $6.03M sold.

Picton Mahoney Asset Management first reported a position in APLS in Q3 2022 and held it in 7 quarters. The position peaked at $6.03M in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

Picton Mahoney Asset Management reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Picton Mahoney Asset Management sold 150,000 Apellis Pharmaceuticals shares in Q2 2026, an estimated $6.03M.
Picton Mahoney Asset Management first reported a position in Apellis Pharmaceuticals in Q3 2022 and held it in 7 quarters.
Picton Mahoney Asset Management's Apellis Pharmaceuticals position peaked at $6.03M in Q1 2026.
1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on Picton Mahoney Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.